Literature DB >> 12196916

Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations.

Taketoshi Yoshida1, Hirokazu Kanegane, Motomi Osato, Masatoshi Yanagida, Toshio Miyawaki, Yoshiaki Ito, Katsuya Shigesada.   

Abstract

Cleidocranial dysplasia (CCD) is an autosomal dominant heritable skeletal disease caused by heterozygous mutations in the osteoblast-specific transcription factor RUNX2. We have performed mutational analysis of RUNX2 on 24 unrelated patients with CCD. In 17 patients, 16 distinct mutations were detected in the coding region of RUNX2: 4 frameshift, 3 nonsense, 6 missense, and 2 splicing mutations, in addition to 1 polymorphism. The missense mutations were all clustered within the Runt domain, and their protein products were severely impaired in DNA binding and transactivation. In contrast, two RUNX2 mutants had the Runt domain intact and remained partially competent for transactivation. One criterion of CCD, short stature, was much milder in the patients with the intact Runt domain than in those without. Furthermore, a significant correlation was found between short stature and the number of supernumerary teeth. On the one hand, these genotype-phenotype correlations highlight a general, quantitative dependency, by skeleto-dental developments, on the gene dosage of RUNX2, which has hitherto been obscured by extreme clinical diversities of CCD; this gene-dosage effect is presumed to manifest on small reductions in the total RUNX2 activity, by approximately one-fourth of the normal level at minimum. On the other hand, the classic CCD phenotype, hypoplastic clavicles or open fontanelles, was invariably observed in all patients, including those with normal height. Thus, the cleidocranial bone formation, as mediated by intramembranous ossification, may require a higher level of RUNX2 than does skeletogenesis (mediated by endochondral ossification), as well as odontogenesis (involving still different complex processes). Overall, these results suggest that CCD could result from much smaller losses in the RUNX2 function than has been envisioned on the basis of the conventional haploinsufficiency model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196916      PMCID: PMC378531          DOI: 10.1086/342717

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  63 in total

1.  Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains.

Authors:  W Y Kim; M Sieweke; E Ogawa; H J Wee; U Englmeier; T Graf; Y Ito
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Authors:  Y Kanno; T Kanno; C Sakakura; S C Bae; Y Ito
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Authors:  Y Kamachi; E Ogawa; M Asano; S Ishida; Y Murakami; M Satake; Y Ito; K Shigesada
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit.

Authors:  T Kanno; Y Kanno; L F Chen; E Ogawa; W Y Kim; Y Ito
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

5.  CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia.

Authors:  G Zhou; Y Chen; L Zhou; K Thirunavukkarasu; J Hecht; D Chitayat; B D Gelb; S Pirinen; S A Berry; C R Greenberg; G Karsenty; B Lee
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

Review 6.  Cleidocranial dysplasia: clinical and molecular genetics.

Authors:  S Mundlos
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

7.  The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.

Authors:  K Tanaka; T Tanaka; M Kurokawa; Y Imai; S Ogawa; K Mitani; Y Yazaki; H Hirai
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

8.  Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.

Authors:  T Nagata; V Gupta; D Sorce; W Y Kim; A Sali; B T Chait; K Shigesada; Y Ito; M H Werner
Journal:  Nat Struct Biol       Date:  1999-07

9.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.

Authors:  M Osato; N Asou; E Abdalla; K Hoshino; H Yamasaki; T Okubo; H Suzushima; K Takatsuki; T Kanno; K Shigesada; Y Ito
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

10.  The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.

Authors:  N Adya; T Stacy; N A Speck; P P Liu
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  54 in total

Review 1.  Transcriptional networks controlling stromal cell differentiation.

Authors:  Alexander Rauch; Susanne Mandrup
Journal:  Nat Rev Mol Cell Biol       Date:  2021-04-09       Impact factor: 94.444

2.  The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation.

Authors:  Wei Zhu; Xinyu He; Yue Hua; Qian Li; Jiyong Wang; Xiaoqing Gan
Journal:  J Biol Chem       Date:  2017-05-12       Impact factor: 5.157

3.  Prolyl isomerase Pin1-mediated conformational change and subnuclear focal accumulation of Runx2 are crucial for fibroblast growth factor 2 (FGF2)-induced osteoblast differentiation.

Authors:  Won-Joon Yoon; Young-Dan Cho; Woo-Jin Kim; Han-Sol Bae; Rabia Islam; Kyung-Mi Woo; Jeong-Hwa Baek; Suk-Chul Bae; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

4.  Aurora kinase-induced phosphorylation excludes transcription factor RUNX from the chromatin to facilitate proper mitotic progression.

Authors:  Linda Shyue Huey Chuang; Jian Ming Khor; Soak Kuan Lai; Shubham Garg; Vaidehi Krishnan; Cheng-Gee Koh; Sang Hyun Lee; Yoshiaki Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-23       Impact factor: 11.205

5.  Clinical and Radiological Evaluation of Cleidocranial Dysplasia in Two Trinidadian Siblings.

Authors:  A K Bissoon; K Moze
Journal:  West Indian Med J       Date:  2014-07-22       Impact factor: 0.171

6.  The role of periodontal ligament cells in delayed tooth eruption in patients with cleidocranial dysostosis.

Authors:  Stefan Lossdörfer; Bassel Abou Jamra; Birgit Rath-Deschner; Werner Götz; Rami Abou Jamra; Bert Braumann; Andreas Jäger
Journal:  J Orofac Orthop       Date:  2009-12-04       Impact factor: 1.938

7.  BMP-2 differentially modulates FGF-2 isoform effects in osteoblasts from newborn transgenic mice.

Authors:  Maria Giovanna Sabbieti; Dimitrios Agas; Luigi Marchetti; J Douglas Coffin; Liping Xiao; Marja M Hurley
Journal:  Endocrinology       Date:  2013-05-28       Impact factor: 4.736

8.  Cleidocranial dysplasia: a rare cause of disproportionate severe short stature.

Authors:  Manzoor Ahmad Bhat; Bashir Ahmad Laway; Suhail Mantoo; Khalid Choudry; Suman Kotwal; Shahnaz Ahmad Mir
Journal:  Oman Med J       Date:  2012-09

9.  A novel small deletion mutation in RUNX2 gene in one Chinese family with cleidocranial dysplasia.

Authors:  Ting Chen; Jin Hou; Ling-Ling Hu; Jie Gao; Bu-Ling Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

10.  Intragenic microdeletion of RUNX2 is a novel mechanism for cleidocranial dysplasia.

Authors:  Ming Ta Michael Lee; Anne Chun-Hui Tsai; Ching-Heng Chou; Feng-Mei Sun; Li-Chen Huang; Pauline Yen; Chyi-Chyang Lin; Chih-Yang Liu; Jer-Yuarn Wu; Yuan-Tsong Chen; Fuu-Jen Tsai
Journal:  Genomic Med       Date:  2008-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.